Scientists discover potent protein that prevents HIV infection

January 10, 2001

In a promising advance in the war against AIDS, scientists have designed a potent, new protein that can prevent HIV infection by blocking its entry into human cells. The protein, called 5-Helix and designed to bind to a region in the HIV coat protein gp41, is able to prevent a wide range of HIV strains from fusing to the cell membrane and thereby infecting it.

The researchers say that the 5-Helix protein could therefore serve as the basis for a new class of broad spectrum, injectible drugs against HIV, one that could be used as an alternative when current drugs fail, i.e., as a salvage therapy. Drugs based on 5-Helix would need to be injected, but could be self-administered much the same way as injectible drugs such as insulin or erythropoeitin are.

The 5-Helix protein could also serve as a basis for prophylactics that could be injected immediately after inadvertent needle pricks in hospital settings to prevent HIV from infecting cells.

These results, from Peter S. Kim and colleagues at the Whitehead Institute for Biomedical Research and the Howard Hughes Medical Institute and published in the January 11 issue of ScienceExpress (an electronic publication of Science magazine highlighting papers from future issues), hold great promise for clinical applications.

Unlike currently used drugs that target HIV at other points during its life cycle--after it has already infected the cell--drugs based on 5-Helix could work by preventing HIV fusion with cell membranes. Such "entry inhibitors" represent a promising and alternative line of attack against HIV. In fact, one entry inhibitor, called T-20, has shown promise in Phase II clinical trials when injected into patients, but it has to be injected in large quantities.

The 5-Helix protein is a potent, broad-spectrum inhibitor of HIV infection that targets a different part of the HIV coat protein than T-20. The researchers are particularly excited by the results they see in the 5-Helix protein. "We may only be a few steps away from seeing whether 5-Helix works in monkeys," says Kim.

This report is the culmination of decades long research into the structure of the HIV coat protein, called gp41. Two years ago, Dr. Kim's lab at the Whitehead Institute used x-ray crystallography to decipher the architecture of gp41. This protein plays a key role in allowing the virus membrane to fuse with the membrane of the cell it is attacking. Scientists have long targeted gp41, hoping that a drug aimed at this protein could nip HIV infection in the bud by blocking the virus' ability to enter cells.

In its inactive form, gp41 lies just beneath the surface of the virus coat, but as HIV prepares to enter a cell, gp41 undergoes a remarkable change. A dormant protein region called the "fusion peptide" is propelled, harpoon-like, toward the host cell membrane, hooking the target for infection. For a fleeting moment, the exposed gp41 is an Achilles' heel for the virus--vulnerable to counterattack by drugs.

The Kim lab designed 5-Helix to bind specifically and tightly to a portion of gp41. Even at nanomolar concentrations, the 5-Helix was able to prevent HIV from entering cells. 5-Helix also has other qualities that make an attractive drug candidate. It is very stable, so it is less likely to be degraded by the body's enzymes; can be made larger to avoid elimination by the kidneys; and modified such that it can escape the body's immune response.

The 5-Helix strategy may have broader application to a wide range of human viruses. Like HIV, many different viruses, including Ebola, HRSV (human respiratory syncytial virus, a leading cause of infant mortality in developed countries), and the flu virus, use a similar fusion membrane strategy to enter cells. The 5-Helix protein can be used as a model to design similar inhibitors against HRSV, for instance.

The 5-Helix results also suggest a new strategy for generating antibodies against HIV, which may be useful in vaccine development.

Next Step
Now that the researchers know that 5-Helix is a potent inhibitor of HIV in cell culture against a wide variety of HIV isolates, the next step is to find out whether or not it has antiviral activity in an animal model. "If 5-Helix-like molecules did work in animals, then the difficult and arduous process of developing it for humans could begin to take place," says Kim.

The American public may have become complacent about the HIV epidemic largely due to the success of the triple cocktail drug therapies. However, worldwide HIV continues to be a major public health menace, infecting more than 33 million people. While developed countries have access to the expensive drugs that suppress HIV infection, many poorer countries with large, infected populations have no treatment options. Even more alarming, the wily virus is mutating to form variants, which escape treatment by the existing drugs. "Current therapy is working, but sexual transmission of virus that is resistant to treatment has been documented, making it important to continue to find new targets and therapies for stopping HIV," says Kim.
-end-


Whitehead Institute for Biomedical Research

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.